AstraZeneca reports 17.05-meter HICKORY result: stock after-hours at EUR 142.20
Published on 10/12/2026 at 18:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- AstraZeneca reported October 11 HICKORY Phase III results for efzimfotase alfa.
- The trial showed a 17.05-meter numerical improvement versus placebo at week 25, without statistical significance.
- AstraZeneca stock was at EUR 142.20 after-hours at Lang & Schwarz on October 12, 2026.
On October 11, 2026, AstraZeneca reported results from the HICKORY Phase III trial of investigational efzimfotase alfa. The trial showed a numerical 17.05-meter improvement versus placebo in the Six-Minute Walk Test at week 25, but the primary endpoint did not achieve statistical significance, according to the AstraZeneca.
AstraZeneca stock was at EUR 142.20 after-hours at Lang & Schwarz on October 12, 2026, at 5:53 p.m. CEST. The bid was EUR 141.90 and the ask was EUR 142.50. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of AstraZeneca stock.
Daily balance
The available trading indication ranged from the EUR 141.90 bid to the EUR 142.50 ask. The FTSE 100 stood at 10,644.02 points on October 12, 2026.
Tomorrow: the next regular Xetra session is scheduled for October 13, 2026.
More news and analysis on AstraZeneca stock
Market context: Market report FTSE 100.
